Psilocybin - MYND Life Sciences
Alternative Names: MYND 604; MYND 778Latest Information Update: 08 Jan 2022
Price :
$50 *
At a glance
- Originator MYND Life Sciences
- Developer MYND Life Sciences; University of British Columbia
- Class Analgesics; Anti-infectives; Anti-inflammatories; Antidepressants; Antineoplastics; Antipsychotics; Anxiolytics; Behavioural disorder therapies; Dimethylamines; Drug withdrawal therapies; Indoles; Mood stabilisers; Neuropsychotherapeutics; Organophosphorus compounds; Phytotherapies; Small molecules
- Mechanism of Action ATP-binding cassette transporter modulators; Serotonin 5-HT2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease; Dementia; Major depressive disorder; Sepsis
Most Recent Events
- 15 Dec 2021 MYND Life Sciences completes filing for patent protection related to depression gene modulation pathway
- 15 Oct 2021 MYND Life Sciences plans a phase III trial for Major depressive disorder in Australia
- 13 Oct 2021 MYND Life Sciences in collaboration with Monash University, Deakin University and the University of Sydney plans a phase IIb trial for Major depressive disorder in Australia